Register
Login:
Share:
Email Facebook Twitter


Ariana forecast 47% rise in Kiziltepe gold production


Futura Medical Share Chat (FUM)



Share Price: 34.00Bid: 33.50Ask: 34.50Change: 0.00 (0.00%)No Movement on Futura Med.
Spread: 1.00Spread as %: 2.99%Open: 33.00High: 34.25Low: 33.00Yesterday’s Close: 34.00


Share Discussion for Futura Medical


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


goldust88
Posts: 1,174
Off Topic
Opinion:No Opinion
Price:34.00
Whats next ?
Fri 11:37
Latest interview just to refresh all on what's due here-very soon

http://youtu.be/IPxRKqMPfeQ
 
thomasbrowne
Posts: 206
Observation
Opinion:Strong Buy
Price:33.75
RE: Viagra for sale over counter:
Tue 00:27
Well this is also good news for our med gel , the selling of our med gel'' OTC '' should happen much quicker now. If viagra can do it, then we should find it even easier now. And as I stated before I'm expecting a large percentage of viagra users to use both products together. And including all viagra type pills ,,, who wouldn't want to use the fastest erectile enhancer in the world,,,,,,,,and alongside the greatest erectile enhancing pills. Most people will want to use our MED GEL,,,, exciting times a head,,,,
AIMHO,,,,,,GLA
Fuzzbox
Posts: 395
Off Topic
Opinion:No Opinion
Price:33.75
Viagra for sale over counter:
Mon 23:14
thomasbrowne
Posts: 206
Off Topic
Opinion:No Opinion
Price:33.75
RE: TRADES
Mon 21:27
A internal error caused that double post ,,,,,,,Phillips.....LOL
thomasbrowne
Posts: 206
Answer
Opinion:Strong Buy
Price:33.75
RE: TRADES
Mon 21:25
Reflex if the 400.000 buy late on Friday had of been done earlier and flagged up earlier there's every possibility that it would have increased the SP ? Probably a little, I'm guessing it was a investor closing a short position / somebody selling shares, hoping to see a retrace SP of 29p and panicked late on Friday in case any news came in / results ,PK study or more, and the SP shooting upwards loosing them a fortune,
And that 400.000 buy was them closing that position, there was earlier in the week a 300.000 and 100.000 sell, so that makes sense for me.
The larger amount of buys against sells today should in theory have slightly increased the SP, but I suspect the MARKET MAKERS know that sensitive news flow is imminent and are treading water / in a manner of speaking.with the result being todays unusual slight decline with more buys than sells.
AIMHO ,,,,,,GLA
thomasbrowne
Posts: 206
Answer
Opinion:Strong Buy
Price:33.75
RE: TRADES
Mon 21:24
Reflex if the 400.000 buy late on Friday had of been done earlier and flagged up earlier there's every possibility that it would have increased the SP ? Probably a little, I'm guessing it was a investor closing a short position / somebody selling shares, hoping to see a retrace SP of 29p and panicked late on Friday in case any news came in / results ,PK study or more, and the SP shooting upwards loosing them a fortune,
And that 400.000 buy was them closing that position, there was earlier in the week a 300.000 and 100.000 sell, so that makes sense for me.
The larger amount of buys against sells today should in theory have slightly increased the SP, but I suspect the MARKET MAKERS know that sensitive news flow is imminent and are treading water / in a manner of speaking.with the result being todays unusual slight decline with more buys than sells.
AIMHO ,,,,,,GLA
Reflex
Posts: 493
Off Topic
Opinion:No Opinion
Price:33.75
TRADES
Mon 19:41
Is the LSE website reporting the trades correct?
I can just stumped after how the buy yesterday didn't raise the SP opening price.
Further stumped how we have again more buys than sells and still finished down.
thomasbrowne
Posts: 206
Observation
Opinion:Strong Buy
Price:33.75
RE: -ve for competitor
Mon 17:40
Vitaros was a poorly performing sexual enhancer with the 2.5 % dose of its active ingredient , never mind it's difficulties when actually applying or injecting the cream, down into the male urethra, which I personally find that difficult to understand / awkward, and that alone must deter many people from even trying it.
So the FDA has asked for its active ingredients to be reduced to 0.5 % which in my opinion will make it ineffective or more accurately redundant and should be binned or sold for a nominal sum in case it's ingredients has some other applications in medicine.
The data for its 2.5% active ingredients was poor around its percentage of people it actually worked on ,,,,IMHO,,,,, so it's effectively a dead product at the 0.5% dose .
The FDA gave APRICUS 2 attempts at getting vitaros approved and over several long years and it just wasn't possible. And I'm astonished that the EMA is not taking a second look at VATAROS and rejecting it like the USA .

IN short it's a great result for our MED GEL . But I genuinely believe our MED gel would have taken this whole market anyway. And our own bussiness model is built around a tried and tested long established
Medications that can be reformulated to easily and quickly penetrate our skin. And that makes it safer and cheaper to get these reformulated products to market. ....it doesn't mean there's any guarantees, but it's substantially and statically much safer operating our bussiness model compared to the big pharmaceutical companies, pfizer spend $ 8 billion dollars per year in R&D
So hopefully everything will run smoothly going into our 3rd trial and licensing contracts, the safety data on our active ingredient GTN/ MED GEL has been proven with data over nearly a 100 years ,and continues to be safely used in spray and pill form,and now put into a gel form......that's why futuras business model is so compelling ,and I believe beyond our med gel there is numerous other applications for our technology,,
It's actually what the market needs and asking for, especially with our pain portfolio.
AIMHO,,,,,GLA
cadburyhill
Posts: 374
Observation
Opinion:Strong Buy
Price:34.10
-ve for competitor
Mon 13:58
A blow - excuse the pun - to an erectile dysfunction peer/ competitor product....it£s too expensive to hit FDA requirements...rights to be sold.

FDA Confirms Vitaros Regulatory Pathway

�Company Seeking Partner to Develop Vitaros in U.S.

Company Evaluating Strategic Alternatives

SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of its end-of-review meeting with the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Vitaros(TM)�(alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.�

The preliminary end-of-review meeting minutes support a plan to address issues cited by the FDA in its February 15, 2018 Complete Response Letter (CRL) for the Vitaros NDA.� Specifically, the FDA confirmed during the meeting that the company should develop a new Vitaros formulation that reduces the concentration of DDAIP.HCl from 2.5% to 0.5% in order to address the tumor promotion and partner transference safety concerns noted in the CRL.� The FDA also confirmed that two new Phase 3 clinical efficacy trials with the reformulated product should be conducted prior to resubmitting the NDA and that the trials should include an assessment of the potential risk of enhanced sexually transmitted infections with the new formulation. In addition, the FDA requested certain pharmacokinetic assessments that we expect can be completed as part of the requested Phase 3 program and any additional clinical or commercial safety data generated prior to a resubmission. �Lastly, the FDA stated that the Chemistry, Manufacturing and Control (CMC) section in the resubmission will need to be updated with data generated during development of the new formulation.

The FDA previously issued a CRL for the Vitaros NDA, indicating that it could not approve the NDA for Vitaros in its present form, identifying deficiencies related to CMC and whether the modest treatment effect of Vitaros outweighed certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation.�

"While we are pleased that the FDA has outlined a clear regulatory pathway for Vitaros, which we believe provides a path to approval in the U.S., the cost and timeline associated with a reformulation effort and completing additional phase 3 clinical trials exceeds our current resources and our ability to raise additional capital.� Therefore, we have initiated discussions with interested parties for the U.S. Vitaros rights to enable its continued development and potential approval in exchange for financial terms commensurate with a development stage asset.� In parallel, the Board of Directors has determined that Apricus should evaluate strategic alternatives or othe
Bobsfa
Posts: 835
Observation
Opinion:No Opinion
Price:34.10
Tomorrow
Sun 21:21
Here's hoping for a good week of news and upward movement.
B




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.